Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jan 18;10(1):22.
doi: 10.3390/cancers10010022.

AR Signaling in Human Malignancies: Prostate Cancer and Beyond

Emmanuel S Antonarakis  1
Affiliations
Editorial

AR Signaling in Human Malignancies: Prostate Cancer and Beyond

Emmanuel S Antonarakis. Cancers (Basel). .

Abstract

The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This special issue of Cancers initially reviews the role of AR in advanced prostate cancer, and then explores the potential importance of AR signaling in other epithelial malignancies. The first few articles focus on the use of novel AR-targeting therapies in castration-resistant prostate cancer and the mechanisms of resistance to novel antiandrogens, and they also outline the interaction between AR and other cellular pathways, including PI3 kinase signaling, transcriptional regulation, angiogenesis, stromal factors, Wnt signaling, and epigenetic regulation in prostate cancer. The next several articles review the possible role of androgens and AR signaling in breast cancer, bladder cancer, salivary gland cancer, and hepatocellular carcinoma, as well as the potential treatment implications of using antiandrogen therapies in these non-prostatic malignancies.

PubMed Disclaimer

Conflict of interest statement

E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis, and Merck and has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; he is also the co-inventor of a biomarker technology that has been licensed to Qiagen.

References

    1. Schweizer M.T., Yu E.Y. AR-signaling in human malignancies: Prostate cancer and beyond. Cancers. 2017;9:7. doi: 10.3390/cancers9010007. - DOI - PMC - PubMed
    1. Crumbaker M., Khoja L., Joshua A.M. AR signaling and the PI3K pathway in prostate cancer. Cancers. 2017;9:34. doi: 10.3390/cancers9040034. - DOI - PMC - PubMed
    1. Obinata D., Takayama K., Takahashi S., Inoue S. Crosstalk of the androgen receptor with transcriptional collaborators: potential therapeutic targets for castration-resistant prostate cancer. Cancers. 2017;9:22. doi: 10.3390/cancers9030022. - DOI - PMC - PubMed
    1. Eisermann K., Fraizer G. The androgen receptor and VEGF: Mechanisms of androgen-regulated angiogenesis in prostate cancer. Cancers. 2017;9:32. doi: 10.3390/cancers9040032. - DOI - PMC - PubMed
    1. Leach D.A., Buchanan G. Stromal androgen receptor in prostate cancer development and progression. Cancers. 2017;9:10. doi: 10.3390/cancers9010010. - DOI - PMC - PubMed

Publication types

LinkOut - more resources